Quarterly ResultMay 14, 2026, 04:23 PM
RenovoRx Q1 Revenue $563K, +136% QoQ; Cash $12.4M; TIGeR-PaC Enrollment Near
AI Summary
RenovoRx reported record first-quarter 2026 financial results, with revenue reaching $563,000, a 136% increase quarter-over-quarter and exceeding 50% of full-year 2025 revenue. The company expanded its active commercial cancer center customers to 16 and expects full enrollment for its Phase III TIGeR-PaC trial in June 2026. RenovoRx also strengthened its balance sheet with $12.4 million in cash, sufficient to fund operations into at least the second half of 2027, partly due to a $10 million private placement. The company reiterated its full-year 2026 revenue guidance of $3 million to $4 million.
Key Highlights
- Q1 2026 revenue was $563,000, a 136% increase quarter-over-quarter.
- Q1 2026 revenue exceeded 50% of total revenue for full year 2025.
- Active commercial cancer centers expanded to 16, up from 5 at start of 2025.
- Ended Q1 2026 with $12.4 million in cash and cash equivalents.
- Successfully completed a private placement, generating $10 million in gross proceeds.
- Net loss for Q1 2026 was $3.5 million, compared to $2.4 million in Q1 2025.
- Reiterated full-year 2026 revenue guidance of $3 million to $4 million.
- Phase III TIGeR-PaC trial expects full enrollment by June 2026, with 93% randomized.